Clinical Trials Browser

Phase 1/2 × Trastuzumab × Breast × Clear all

NCT06324357 2026-04-15

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT05785741 2026-04-06

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms

NCT03101748 2026-02-12

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1/2 Terminated

34 enrolled 15 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05256745 2025-12-24

RAGE

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

NCT07136428 2025-12-19

ASCENdANT

Phase 1/2 Not yet recruiting

HER2+ Metastatic Breast Cancer

NCT01373710 2025-11-24

HIT

Phase 1/2 Completed

Breast Neoplasms, Meningeal Carcinomatosis

NCT04108858 2025-10-01

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Phase 1/2 Terminated

2 enrolled 6 charts

Breast Neoplasms

NCT06027983 2025-09-23

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

Phase 1/2 Not yet recruiting

BreastOther solid neoplasm

HER2+ Advanced Breast Cancer

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

Anatomic Stage II Breast Cancer AJCC v8

NCT00317720 2025-04-30

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Phase 1/2 Completed

40 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis

NCT01084863 2025-01-24

Compare

Phase 1/2 Completed

143 enrolled 23 charts

Breast Neoplasms

NCT05555251 2024-12-16

CONTRAST

Phase 1/2 Terminated

BreastGastrointestinal

HER2-positive Breast Cancer

NCT03379428 2024-12-06

Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05574881 2024-02-26

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT02066532 2023-08-24

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Phase 1/2 Completed

32 enrolled 13 charts

Breast Neoplasms

NCT00337649 2023-04-28

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT03112590 2023-04-19

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

Phase 1/2 Completed

51 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01922921 2023-04-18

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Phase 1/2 Completed

31 enrolled 8 charts

Breast Neoplasms

NCT01306942 2023-03-30

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1/2 Completed

37 enrolled 30 charts

Breast Neoplasms

NCT00129896 2023-03-06

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Phase 1/2 Completed

Breast Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Phase 1/2 Terminated

201 enrolled 71 charts

BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT02657343 2022-08-01

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

Phase 1/2 Completed

25 enrolled 16 charts

Breast Neoplasms

NCT04512261 2022-07-01

TOPAZ

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

NCT03913234 2022-05-10

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Phase 1/2 Unknown

Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04750122 2021-04-01

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients

Phase 1/2 Recruiting

HER2-positive Early Breast Cancer

NCT04170595 2021-03-03

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

Phase 1/2 Unknown

HER2-positive Breast Cancer

NCT02139358 2021-02-04

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Phase 1/2 Completed

15 enrolled 12 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02336984 2021-01-11

A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS

Phase 1/2 Withdrawn

NCT00574587 2020-10-14

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Phase 1/2 Completed

55 enrolled 10 charts

Breast Neoplasms

NCT00033514 2020-10-08

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Phase 1/2 Completed

27 enrolled 12 charts

Breast Neoplasms

NCT03994107 2020-01-22

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Phase 1/2 Terminated

16 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis

NCT04152057 2019-11-05

Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer

Phase 1/2 Unknown

Breast Neoplasms

NCT02318901 2019-10-21

PembroMab

Phase 1/2 Terminated

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT01325207 2019-09-26

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

Phase 1/2 Completed

34 enrolled 14 charts

Breast Neoplasms

NCT02843126 2019-09-12

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Phase 1/2 Completed

Breast Neoplasms

NCT02297230 2018-10-15

Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics

Phase 1/2 Terminated

44 enrolled 6 charts

Breast Neoplasms

NCT00398567 2018-07-24

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Phase 1/2 Completed

45 enrolled 15 charts

Breast Neoplasms

NCT00006123 2018-05-16

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT02379585 2018-04-24

STEFNE

Phase 1/2 Terminated

8 enrolled 1 chart

HER2-positive Breast Cancer

NCT02345772 2018-02-20

Neohttp

Phase 1/2 Terminated

4 enrolled 1 chart

HER2-positive Breast Cancer

NCT00864175 2018-01-18

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms

NCT01512199 2017-10-18

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Phase 1/2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT00331552 2017-07-26

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1/2 Completed

30 enrolled 13 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00041470 2017-07-17

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Phase 1/2 Terminated

38 enrolled 6 charts

Breast Neoplasms